Bromide

Bromide

SCHEMBL3601825

[Br-].c1ccc(C[n+]2ccc3ccccc3c2)cc1

nearest known ligand 0.89

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ACHE known ✓ P22303 18/20 0.89
BCHE P06276 19/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127774 0.98 ACHE (0.85) ACHEBCHE
Hydrochloric Acid SCHEMBL8870693 0.96 ACHE (0.81) ACHEBCHE
SCHEMBL6767708 0.83 ACHE (0.79) ACHEBCHE
SCHEMBL8870095 0.82 ACHE (0.61) ACHEBCHE
Bromide SCHEMBL23535338 0.81 ACHE (0.60) ACHEBCHE
SCHEMBL23259016 0.79 ACHE (0.57) ACHEBCHE
SCHEMBL23258819 0.79 ACHE (0.57) ACHEBCHE
SCHEMBL6771128 0.79 ACHE (0.76) ACHEBCHE
SCHEMBL21750879 0.79 ACHE (0.56) ACHEBCHE
SCHEMBL9565169 0.78 BCHE (0.66) ACHEBCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200062783-A1 PHOTO LEWIS ACID GENERATOR NIPPON SHOKUBAI CO., LTD. (JP) 2020-02-27 US disclosed
EP-2118102-B1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES SRL (IT) 2013-06-12 EP disclosed
US-8207180-B2 Tricyclic indoles and (4,5-dihydro) indoles NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2012-06-26 US disclosed
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-03-25 US disclosed
EP-2118102-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES Nerviano Medical Sciences S.r.l. (IT) 2009-11-18 EP disclosed
WO-2008065054-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075998-A1 TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES CDC7, CDK7, CDK17 ACHE 3448/4885BCHE 3301/4885
US-20200062783-A1 PHOTO LEWIS ACID GENERATOR LEO1, LRRK2, LSG1 ACHE 4068/4885BCHE 3567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.